Juvenile Chronic Myelogenous Leukemia (JCML)

Jay L Hess

Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 413b Stellar Chance Laboratories, Philadelphia, PA 19104, USA (JLH)

Published in Atlas Database: December 2000
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/JCMLID1099.html
DOI: 10.4267/2042/37702
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2001 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Alias
Juvenile myelomonocytic leukemia (JMML)
Juvenile myelomonocytic leukemia syndrome (JMML syndrome)

Note
The proper terminology of this disorder is controversial; many authors, including the European Working Group on MDS in Childhood favor the term JMML; another working group suggests using the term JMML syndrome with a qualifier with or without monosomy 7 or 7q.

Clinics and pathology

Disease
JCML is a chronic myeloproliferative disorder that typically affects young children: more than 95% of cases are diagnosed before age 4.

Phenotype/cell stem origin
Evidence exists for leukemic involvement of CD34-positive stem cells and monocyte-macrophage, erythroid, and B-lymphoid lineages in cases with cytogenetic abnormalities.

Epidemiology
Annual incidence is estimated to be roughly 4/million; median age 1-4 yrs; sex ratio: 1.4M/1F.

Clinics
Splenomegaly, lymphadenopathy, and skin rash are common; typical peripheral blood findings include leukocytosis (usually less than 100 x 10^9/L), monocytosis, and thrombocytosis with variable degree of left shift; myeloblasts average about 5% of total nucleated cells; elevation of fetal hemoglobin (hbF) very common; absence of the Philadelphia chromosome in all cases.

Proposed clinical criteria from the International Juvenile Myelomonocytic Leukemia Working Group includes:
1. White blood cell count > 13 x 10^9/L (corrected for nucleated red blood cells).
2. Absolute monocyte count >1 x 10^9/L (corrected).
3. Presence of immature myeloid precursors (myelocytes, promyelocytes, and myeloblasts) in the peripheral blood.
4. Bone marrow aspirate revealing < 30% blasts
5. No Ph chromosome on cytogenetic assessment.
About 15% of cases are associated with neurofibromatosis type 1 (NF-1 mutation).

Pathology
Blood: leukocytosis, monocytosis, left shift in myeloid maturation, circulating nucleated red blood cells.
Bone marrow: hypercellular marrow with mildly increased M:E ratio (typically 5:1), dispersed erythroid elements, and decreased numbers of megakaryocytes; dysplasia is usually not prominent.

Treatment
Intensive chemotherapy and all trans retinoic have not been shown to induce durable remissions; complete remissions have been achieved with stem cell transplantation.

Prognosis
The disease is uniformly fatal when treated with conventional chemotherapy; among those who undergo bone marrow transplantations, the majority ultimately relapse, with an overall survival rate of 25%.
Juvenile Chronic Myelogenous Leukemia (JCML) Hess JL

Cytogenetics

Cytogenetics morphological

Other than the frequent association with monosomy 7, no consistent cytogenetic abnormalities have been identified; whether the infantile monosomy 7 syndrome is distinct from JCML is controversial.

Genes involved and proteins

Note

Mechanisms of Oncogenesis:

JCML patients show spontaneous growth of granulocyte-macrophage colony forming units (CFU-GM) from peripheral blood, which appears to be the result of hypersensitivity to GM-CSF, IL-3, or SCF; cases associated with NF-1 are likely to be the result of constitutive activation of the Ras pathway as a result of decreased GT Pase activity although there is also evidence of a GAP independent function; up to 30% of cases show mutations in K-ras and N-ras; the importance of the RAS pathway has been confirmed in mouse models with targeted disrupted of Nf-1; recently data suggest that TNFα produced by neoplastic cells may prevent expansion of hematopoietic progenitors.

References


This article should be referenced as such: